Skip to content
The Nexus
DossierENTITY

Palvella Therapeutics, Inc.

Coverage of Palvella Therapeutics, Inc. in the Nexus archive.

Earliest in view: Aug 4 · 11:40 UTCMost recent: Aug 4 · 11:40 UTC
Co-mentioned in this coverage
Zacks Investment Researchorganization1Automated Insightsorganization1Wayneplace1Pennsylvaniaplace1PVLAtopic1
Recent coverage
  • BUSINESSAug 4 · 11:40 UTCWTOP DC
    Palvella Therapeutics: Q2 Earnings Snapshot

    Palvella Therapeutics reported a second-quarter loss of $21.9 million, or $1.52 per share, missing Wall Street expectations of a $1.16 per share loss. The results were generated by Automated Insights using data from Zacks Investment Research.

Palvella Therapeutics, Inc. · Dossier · The Nexus